共 50 条
Targeted therapies in hepatocellular carcinoma: past, present, and future
被引:1
|作者:
Gujarathi, Rushabh
[1
]
Franses, Joseph W.
[1
]
Pillai, Anjana
[2
]
Liao, Chih-Yi
[1
]
机构:
[1] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Chicago, IL USA
来源:
关键词:
hepatocellular carcinoma;
targeted therapy;
clinical trials;
tyrosine kinase inhibitors;
immunotherapy;
GROWTH-FACTOR-BETA;
RECEPTOR TYROSINE KINASES;
CELL LUNG-CANCER;
C-MET;
TGF-BETA;
LIVER-CANCER;
SORAFENIB RESISTANCE;
ANTITUMOR-ACTIVITY;
SIGNALING PATHWAY;
1ST-LINE THERAPY;
D O I:
10.3389/fonc.2024.1432423
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Targeted therapies are the mainstay of systemic therapies for patients with advanced, unresectable, or metastatic hepatocellular carcinoma. Several therapeutic targets, such as c-Met, TGF-beta, and FGFR, have been evaluated in the past, though results from these clinical studies failed to show clinical benefit. However, these remain important targets for the future with novel targeted agents and strategies. The Wnt/beta-catenin signaling pathway, c-Myc oncogene, GPC3, PPT1 are exciting novel targets, among others, currently undergoing evaluation. Through this review, we aim to provide an overview of previously evaluated and potentially novel therapeutic targets and explore their continued relevance in ongoing and future studies for HCC.
引用
收藏
页数:16
相关论文